SG11201706268XA - Tnfrsf-binding agents and uses thereof - Google Patents

Tnfrsf-binding agents and uses thereof

Info

Publication number
SG11201706268XA
SG11201706268XA SG11201706268XA SG11201706268XA SG11201706268XA SG 11201706268X A SG11201706268X A SG 11201706268XA SG 11201706268X A SG11201706268X A SG 11201706268XA SG 11201706268X A SG11201706268X A SG 11201706268XA SG 11201706268X A SG11201706268X A SG 11201706268XA
Authority
SG
Singapore
Prior art keywords
tnfrsf
uses
binding agents
binding
agents
Prior art date
Application number
SG11201706268XA
Inventor
Austin L Gurney
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201562111404P priority Critical
Priority to US201562153272P priority
Priority to US201562154008P priority
Priority to US201562218956P priority
Priority to US201562259129P priority
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Priority to PCT/US2016/016306 priority patent/WO2016126781A1/en
Publication of SG11201706268XA publication Critical patent/SG11201706268XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11201706268XA 2015-02-03 2016-02-03 Tnfrsf-binding agents and uses thereof SG11201706268XA (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US201562111404P true 2015-02-03 2015-02-03
US201562153272P true 2015-04-27 2015-04-27
US201562154008P true 2015-04-28 2015-04-28
US201562218956P true 2015-09-15 2015-09-15
US201562259129P true 2015-11-24 2015-11-24
PCT/US2016/016306 WO2016126781A1 (en) 2015-02-03 2016-02-03 Tnfrsf-binding agents and uses thereof

Publications (1)

Publication Number Publication Date
SG11201706268XA true SG11201706268XA (en) 2017-08-30

Family

ID=56564627

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706268XA SG11201706268XA (en) 2015-02-03 2016-02-03 Tnfrsf-binding agents and uses thereof

Country Status (16)

Country Link
US (2) US9724390B2 (en)
EP (1) EP3253890A4 (en)
JP (1) JP2018508233A (en)
KR (1) KR20170108073A (en)
CN (2) CN107406878A (en)
AU (1) AU2016215394A1 (en)
BR (1) BR112017016705A2 (en)
CA (1) CA2975596A1 (en)
CO (1) CO2017008047A2 (en)
EA (1) EA201791313A1 (en)
IL (1) IL253433D0 (en)
MX (1) MX2017009793A (en)
PH (1) PH12017501372A1 (en)
SG (1) SG11201706268XA (en)
TW (1) TW201643184A (en)
WO (1) WO2016126781A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604693T3 (en) * 2008-07-21 2016-09-30 TNFSF single chain molecules
AU2013326901B2 (en) * 2012-10-04 2018-05-31 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-PD-L1 antibodies and methods of use
CN105492017A (en) 2013-07-19 2016-04-13 弗拉芒区生物技术研究所 Targeted modified tnf family members
MX2017009793A (en) 2015-02-03 2017-10-27 Oncomed Pharm Inc Tnfrsf-binding agents and uses thereof.
US10046047B2 (en) * 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
AU2016233495A1 (en) 2015-03-13 2017-10-26 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
MX2018000621A (en) 2015-07-13 2018-05-11 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof.
WO2017059168A1 (en) 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
EP3585409A1 (en) 2017-02-27 2020-01-01 Shattuck Labs, Inc. Csf1r-based chimeric proteins
AU2018224852A1 (en) * 2017-02-27 2019-07-11 Shattuck Labs, Inc. VSIG8-based chimeric proteins
WO2018160572A1 (en) * 2017-02-28 2018-09-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising gitr-binding agents
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
WO2019032945A1 (en) * 2017-08-10 2019-02-14 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
WO2019237383A1 (en) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Modified vector used for human tnfsf18 gene editing, preparation method therefor and application thereof
CN109912717A (en) * 2019-03-04 2019-06-21 北京天广实生物技术股份有限公司 In conjunction with the antibody and application thereof of CD40

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926888T2 (en) 1988-01-22 1997-01-09 Zymogenetics Inc A process for producing secreted receptor analogs
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US5998171A (en) 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
EP0961831B1 (en) 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Human endokine alpha
IL135911D0 (en) 1997-11-18 2001-05-20 Genentech Inc Dna 19355 polypeptide, a tumor necrosis factor homolog
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
DK1060247T3 (en) 1998-02-24 2009-01-26 Sisters Of Providence In Orego Composition containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-h1, an unknown immune regulatory molecule
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
DE19963859A1 (en) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- or oligomer of a di-, tri-, or Quattro pentamer of recombinant fusion proteins
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
DE10122140A1 (en) 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Recombinant fusion proteins and their trimers
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
WO2003070763A1 (en) 2001-08-16 2003-08-28 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US20030232323A1 (en) 2001-11-13 2003-12-18 Wyeth Agents that modulate immune cell activation and methods of use thereof
EP1516054B1 (en) 2002-02-10 2009-12-02 Topotarget Switzerland SA Fusion constructs containing active sections of tnf ligands
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
IL164376D0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
ES2654064T1 (en) 2002-07-03 2018-02-12 Ono Pharmaceutical Co., Ltd. Immunopotentiation compositions comprising anti-PD-L1 antibodies
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CN101899106A (en) 2002-10-29 2010-12-01 阿纳福公司 Trimeric binding proteins for trimeric cytokines
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
MXPA05012475A (en) 2003-05-23 2006-05-25 Wyeth Corp Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof.
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
DE102004014983A1 (en) 2004-03-26 2005-10-20 Univ Stuttgart Recombinant polypeptides of the members of the TNF ligand family and their use
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
PL1810026T3 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-h1 and pd-1 in treatment of renal cell carcinoma
CN101072578A (en) 2004-10-29 2007-11-14 南加州大学 Combination cancer immunotherapy with co-stimulatory molecules
JP5238936B2 (en) 2005-03-25 2013-07-17 ジーアイティーアール,インク.GITR, Inc. GITR binding molecules and uses thereof
DK2650020T3 (en) 2005-05-06 2017-01-16 Providence Health & Services - Oregon Trimeric OX40 immunoglobulin fusion protein and methods for applications.
CA2607291A1 (en) 2005-05-12 2006-11-23 Steven D. Levin Compositions and methods for modulating immune responses
AU2006254902B8 (en) 2005-06-08 2012-08-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
ME02260B (en) 2005-07-01 2016-02-29 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20080286286A1 (en) 2006-01-13 2008-11-20 Board Of Regents, The University Of Texas System Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
WO2007111931A2 (en) 2006-03-22 2007-10-04 Imperial Innovations Limited Compositions and methods relating to modulation of immune system components
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
HUE030139T2 (en) 2006-12-27 2017-04-28 Univ Emory Compositions and methods for the treatment of infections
EP2009022A1 (en) 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
ES2567704T3 (en) 2007-07-10 2016-04-26 Apogenix Gmbh TNF superfamily colectin fusion proteins
CN101801413A (en) 2007-07-12 2010-08-11 托勒克斯股份有限公司 Combination therapies employing GITR binding molecules
US20090136446A1 (en) 2007-11-02 2009-05-28 Ludwig Institute For Cancer Research Ltd. Induction of regulatory t cell-resistant helper cd4+ t cells
DK2279412T3 (en) 2008-04-09 2017-10-16 Genentech Inc Present unknown compositions and procedures for treating immunrated diseases
PL2604693T3 (en) 2008-07-21 2016-09-30 TNFSF single chain molecules
JPWO2010030002A1 (en) 2008-09-12 2012-02-02 国立大学法人三重大学 Foreign GITR ligand expressing cells
CN102282265A (en) 2008-11-28 2011-12-14 埃默里大学 A method for the treatment of infectious diseases and cancer
ES2593049T3 (en) 2009-01-09 2016-12-05 Apogenix Ag Fusion proteins that form trimers
CN103641918A (en) 2009-03-13 2014-03-19 宾夕法尼亚大学董事会 OX40/TRAIL fusion proteins
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
SI2504364T1 (en) 2009-11-24 2017-11-30 Medimmune Limited Targeted binding agents against b7-h1
EP3260470A1 (en) 2010-03-05 2017-12-27 The John Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
PT2609118T (en) 2010-08-23 2017-03-22 Univ Texas Anti-ox40 antibodies and methods of using the same
AU2012237456B2 (en) 2011-04-01 2017-06-29 Universitat Stuttgart Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereof
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
TWI476001B (en) 2011-12-26 2015-03-11 Ind Tech Res Inst Trimeric fc fusion and uses thereof
WO2013107413A1 (en) 2012-01-19 2013-07-25 中国科学院上海巴斯德研究所 Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
AU2012369202A1 (en) 2012-02-06 2014-09-25 Providence Health & Services - Oregon Cancer treatment and monitoring methods using OX40 agonists
MX2014013565A (en) 2012-05-15 2015-02-12 Squibb Bristol Myers Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling.
CN104936982A (en) 2012-08-03 2015-09-23 丹娜法伯癌症研究院 Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
US10081759B2 (en) 2012-10-09 2018-09-25 Eric John Wernimont Method, apparatus, and composition for increased recovery of hydrocarbons by paraffin and asphaltene control from reaction of fuels and selective oxidizers in the subterranean environment
MX363188B (en) 2012-11-30 2019-03-13 Hoffmann La Roche Identification of patients in need of pd-l1 inhibitor cotherapy.
PT2925350T (en) 2012-12-03 2019-03-25 Squibb Bristol Myers Co Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
CN105026424A (en) 2013-01-01 2015-11-04 卡尔医疗有限公司 Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
AU2014233114B2 (en) * 2013-03-15 2018-03-08 Richard S. Kornbluth Composition comprised of antigen linked to a TNF SuperFamily ligand
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
SG11201600310QA (en) 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
CN105492017A (en) 2013-07-19 2016-04-13 弗拉芒区生物技术研究所 Targeted modified tnf family members
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulation of tumor immunity
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
EP3161003A2 (en) 2014-06-27 2017-05-03 Apogenix GmbH Combination of cd95/cd95l inhibition and cancer immunotherapy
US9914761B2 (en) 2014-07-10 2018-03-13 Washington University Oligomers for TNF superfamily inhibition
JP2017525370A (en) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing and using tumor necrosis factor superfamily and TNF-like ligand muteins
KR20170065029A (en) 2014-10-08 2017-06-12 노파르티스 아게 Compositions and methods of use for augmented immune response and cancer therapy
TW201625270A (en) 2014-11-11 2016-07-16 梅迪繆思有限公司 Therapeutic combinations and methods for treating neoplasia
EP3224275A1 (en) 2014-11-14 2017-10-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
MX2017009793A (en) 2015-02-03 2017-10-27 Oncomed Pharm Inc Tnfrsf-binding agents and uses thereof.
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
MX2017012805A (en) 2015-04-07 2018-04-11 Genentech Inc Antigen binding complex having agonistic activity and methods of use.
BR112018001161A2 (en) 2015-07-23 2018-09-18 Inhibrx Lp multispecific and multivalent gitr-binding fusion proteins
US10428131B2 (en) 2015-08-12 2019-10-01 Medimmune Limited GITRL fusion proteins comprising a human coronin 1a derived trimerization domain
CN108473549A (en) 2015-10-23 2018-08-31 阿珀吉科吉尼科斯股份公司 Single-stranded GITR receptor agonist proteins

Also Published As

Publication number Publication date
CO2017008047A2 (en) 2018-01-05
US10232017B2 (en) 2019-03-19
PH12017501372A1 (en) 2017-12-18
BR112017016705A2 (en) 2018-04-10
CN109180804A (en) 2019-01-11
EP3253890A4 (en) 2018-06-27
TW201643184A (en) 2016-12-16
JP2018508233A (en) 2018-03-29
US20180021407A1 (en) 2018-01-25
EA201791313A1 (en) 2018-02-28
EP3253890A1 (en) 2017-12-13
US20160256527A1 (en) 2016-09-08
US9724390B2 (en) 2017-08-08
IL253433D0 (en) 2017-09-28
CA2975596A1 (en) 2016-08-11
WO2016126781A1 (en) 2016-08-11
AU2016215394A1 (en) 2017-08-03
KR20170108073A (en) 2017-09-26
MX2017009793A (en) 2017-10-27
WO2016126781A4 (en) 2016-10-13
CN107406878A (en) 2017-11-28

Similar Documents

Publication Publication Date Title
IL249186D0 (en) Anti-cd20 glycoantibodies and uses thereof
IL258248D0 (en) Affinity-oligonucleotide conjugates and uses thereof
EP3303379A4 (en) Tigit-binding agents and uses thereof
GB201411197D0 (en) Composition and use thereof
EP3253890A4 (en) Tnfrsf-binding agents and uses thereof
BR112016016289A2 (en) heteroari and uses thereof
ZA201708565B (en) Dispenser assembly and related methods
GB201506913D0 (en) Inductor structure and application thereof
IL258284D0 (en) Anti-lag3 antibodies and uses thereof
IL257263D0 (en) Anti-angptl8 antibodies and uses thereof
GB201512044D0 (en) Application in German
IL252216D0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
SG11201606367YA (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
IL249362A (en) Pesticidal compositions and processes related thereto
IL247262D0 (en) Cannabinoid compositions and uses
IL246987D0 (en) Herteroaryl amides, compositions comprising same and uses thereof
HK1225365A1 (en) Arrangement and elevator
GB201512203D0 (en) Agents,uses and methods
GB2535253B (en) Compositions and methods
AU363632S (en) Pendant
GB2514927B (en) Thiamethoxam and uses thereof
GB2546350B (en) Compositions and methods
SG11201609490QA (en) Polymer-flavonoid conjugate and uses thereof
ZA201801678B (en) Deuterated compounds and uses thereof
GB201401617D0 (en) Novel combination and use